Predictive value of standard serum markers for bone metastases in prostate cancer

Özdemir, Semra; Ersay, Ahmet Reşit; Öztürk, Fulya Koç; Özdemir, B.

doi:10.1186/s12301-021-00170-w

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hasil penelitian ini sejalan dengan studi yang dilakukan Ozdemir et al 16 yaitu hanya ALP yang memiliki nilai diagnostik dan nilai cutoff ALP ialah 76,50 IU/L dengan sensitivitas 80% dan 82,1% spesifisitas dalam memrediksi metastasis tulang pada kanker prostat, sedangkan PSA dan skor Gleason tidak dianggap sebagai parameter yang dapat diandalkan dalam tindak lanjut kasus kanker prostat untuk perkembangan metastasis tulang. Beberapa studi sebelumnya memang telah membuktikan bahwa ALP merupakan prediktor metastasis tulang pada kanker prostat seperti yang dilaporkan Wei et al 17 pada periode Februari 2011 dan Maret 2014 sebanyak 43 pasien yang terdiagnosis kanker prostat dengan metastasis tulang, yang menunjukkan kadar serum ALP dan PSA meningkat pada pasien dengan metastasis tulang, dan deteksi gabungan dari semua penanda dapat meningkatkan nilai prediksi positif.…”

Section: Bahasanunclassified

Penentuan Model Prediktif Metastasis Tulang dan Prognosis Kanker Prostat Menggunakan Alkalin Fosfatase dan Skor Gleason

Merung,

Toreh,

Astram

et al. 2023

MSJ

View full text Add to dashboard Cite

To date, assessment of the prognostic ability based on the relationship between alkaline phosphatase (ALP) to the Gleason score has not been reported. This study aimed to compare ALP with Gleason score as a predictor of prostate cancer prognosis. This was a hospital-based cross sectional study conducted from January 1, 2019 to December 31, 2021. Prostate cancer patient information included demographics, disease history, clinical characteristics, laboratory and radiology tests, and histopathology results. The results showed that the majority had a poor degree of differentiation (Gleason score: 8-10), which was 85.5%. High serum prostate specific antigen (PSA) levels were associated with the scores. The results of ALP were normal in 59.4%, increased in 34.4%, and decreased in 6.3% of patients. The multivariate regression analysis showed that every 10 U/L increase in ALP in the blood of prostate cancer patients on average was associated with a worse prognosis characterized by an increase in Gleason score of about 0.06 points (95% CI 0.03-0.09; p=0.002). In conclusion, serum alkaline phosphatase can be a predictive factor of bone metastases in prostate cancer with a cut value of 102 IU/L. Each increase of 10 IU/L of serum ALP is associated with a worse prognosis in prostate cancer while the Gleason score cannot be a predictive indicator of bone metastases in prostate cancer. Keywords: alkaline phosphatase; prostate specific antigen; Gleason score; prognostic predictor Abstrak: Penilaian kemampuan prognostik kanker prostat berdasarkan hubungan alkalin fosfatase (ALP) dengan skor Gleason sampai saat ini belum pernah dilaporkan. Tujuan penelitian ini untuk membandingkan kadar ALP dengan skor Gleason sebagai prediktor prognosis kanker prostat. Penelitian ini menerapkan desain potong lintang berbasis rumah sakit dari 1 Januari 2019 hingga 31 Desember 2021. Informasi pasien kanker prostat mencakup demografik, riwayat penyakit, karakteristik klinik, hasil pemeriksaan laboratorium dan radiologi, serta data histopatologi. Hasil penelitian memperlihatkan proporsi terbesar memiliki tingkat diferensiasi buruk dengan skor Gleason: 8-10 sebesar 85,5%. Data tingginya kadar prostate specific antigen (PSA) serum berhubungan dengan skor Gleason. Pada penelitian ini ALP dengan hasil normal 59,4%, meningkat 34,4%, menurun 6,3%. Hasil analisis regresi multivariat menunjukkan setiap 10 U/L kenaikan ALP dalam darah pasien kanker prostat rata-rata berhubungan dengan prognosis lebih buruk ditandai oleh peningkatan skor Gleason sekitar 0,06 poin (95% CI 0,03-0,09; p=0,002). Simpulan penelitian ini ialah ALP dapat menjadi faktor prediksi metastase tulang pada kanker prostat dengan nilai potong 102 IU/L. Setiap peningkatan 10 IU/L ALP serum berhubungan dengan prognosis yang lebih buruk pada kanker prostat sedangkan skor Gleason tidak dapat menjadi indikator prediksi metastase tulang pada kanker prostat. Kata kunci: alkaline fosfatase; prostate specific antigen; skor Gleason; prediktor prognosis

show abstract

Section: Bahasanunclassified

Penentuan Model Prediktif Metastasis Tulang dan Prognosis Kanker Prostat Menggunakan Alkalin Fosfatase dan Skor Gleason

Merung,

Toreh,

Astram

et al. 2023

MSJ

View full text Add to dashboard Cite

show abstract

Prostate Cancer: Burden and Correlation with Prostate Specific Antigen Among Screened African Men in Tanzania

Ngowi,

Mremi,

Seif

et al. 2024

RRU

View full text Add to dashboard Cite

Background Serum prostate-specific antigen (PSA) is a widely used maker for prostate cancer (PCa) screening. However, its correlation with PCa varies, partly due to ethnic differences. This study investigated the correlation between PSA and PCa diagnosis as well as the burden of the disease in the Tanzanian community. Methods This community-based PCa screening took place in Northern Tanzania from May 2022 to September 2022, where men aged ≥40 years were involved. Each participant provided 5 milliliters of venous blood for PSA determination. Those with PSA levels >4 ng/mL underwent prostate biopsy. Two pathologists independently evaluated the biopsies. The correlation between PSA and biopsy results was assessed using STATA version 17.0. Results The study included 6164 African men with a mean age of 60±11 years. Of these, 912 (14.8%) had PSA >4 ng/mL, and hence 581 (63.7%) underwent prostate biopsy. A total of 179 men (30.8%) were histologically diagnosed with prostatic adenocarcinoma, whereby 46 (25.7%) had Gleason scores 8–9. Among participants with PSA >20 ng/mL, over 2/3 (64.7%) had PCa, rising to nearly 100% at PSA >100 ng/mL. A positive correlation between PSA levels and PCa/aggressive disease was observed. PSA sensitivity decreased with rising levels, hitting 78.2% at >10ng/mL and 24.6% at >100ng/mL, while specificity increased, peaking at 99.8% for >100ng/mL from 73.9% at >10ng/mL. The optimal PSA cut point was >10ng/mL. PSA demonstrated an 84% overall ability to predict PCa and a 71% ability to predict aggressive disease. Conclusion This study found a notable presence of intermediate-high grade PCa within the community, suggesting the need for regular screening and management. Moreover, PSA demonstrated clinically useful ability in predicting PCa among African men aged 40 years and older.

show abstract

Quantitative evaluation by SPECT/CT of Radionuclide Therapy with Radium-223 Chloride of Bone Metastases in Metastatic Castration-resistant Prostate Cancer

Николаева¹,

Крылов²,

Рыжков

et al. 2022

jour

View full text Add to dashboard Cite

Evaluation of the effectiveness of bone metastasis therapy is an urgent problem for patients with prostate cancer, mainly due to the relationship between bone metastases, survival and quality of life, which directly depends on the correct interpretation of the results of treatment response. It is known that some patients may experience a multidirectional therapeutic effect in the form of a positive response of some bone metastases and the progression of others. In addition, there are now many new therapeutics with different action profiles and often extremely expensive, so it is important to quickly recognize whether true or pseudo-disease progression is occurring, and this is more evident in patients enrolled in clinical trials with fixed protocols, often requiring radiographic assessment early after the start of treatment. Therefore, the use of additional imaging modalities in clinical practice along with PSA assessment may help improve early prediction of outcome and monitor response to therapy in patients with metastatic CRPC, optimizing the use of this costly treatment.

show abstract

Predictive value of standard serum markers for bone metastases in prostate cancer

Cited by 3 publications

References 30 publications

Penentuan Model Prediktif Metastasis Tulang dan Prognosis Kanker Prostat Menggunakan Alkalin Fosfatase dan Skor Gleason

Penentuan Model Prediktif Metastasis Tulang dan Prognosis Kanker Prostat Menggunakan Alkalin Fosfatase dan Skor Gleason

Prostate Cancer: Burden and Correlation with Prostate Specific Antigen Among Screened African Men in Tanzania

Quantitative evaluation by SPECT/CT of Radionuclide Therapy with Radium-223 Chloride of Bone Metastases in Metastatic Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About